

Lei Shi, Dehui Zhang and Liangyu Zhang*

Crystal structure of ethyl 2-amino-4-(3-methoxyphenyl)-5-oxo-4*H*,5*H*-pyrano[3,2-*c*]chromene-3-carboxylate, C₂₂H₁₉NO₆




Table 1: Data collection and handling.

Crystal:	Colourless block
Size:	0.32 × 0.27 × 0.21 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.10 mm ⁻¹
Diffractometer, scan mode:	Bruker APEX-II, φ and ω
$\theta_{\max}$, completeness:	25.0°, >99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	9483, 3365, 0.045
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 2537
$N(\text{param})_{\text{refined}}$:	263
Programs:	Olex2 [9], SHELX [10], Bruker [11]

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	<i>x</i>	<i>y</i>	<i>z</i>	$U_{\text{iso}}^*/U_{\text{eq}}$
N1	0.49560(16)	0.37245(8)	0.40727(11)	0.0483(4)
H1A	0.483575	0.418000	0.433799	0.058*
H1B	0.454648	0.360356	0.343060	0.058*
O1	0.75159(14)	0.40343(6)	0.71414(9)	0.0498(3)
O2	0.61551(16)	0.46330(7)	0.57665(10)	0.0599(4)
O3	0.57946(12)	0.25269(6)	0.40508(9)	0.0421(3)
O4	0.93243(14)	0.13463(7)	0.65864(9)	0.0536(4)
O5	0.89809(14)	0.09037(7)	0.48794(9)	0.0511(3)
O6	0.57235(15)	0.23129(8)	1.00681(10)	0.0620(4)
C1	0.8455(3)	0.46517(13)	0.88042(17)	0.0817(7)
H1C	0.867432	0.514263	0.915277	0.123*
H1D	0.775872	0.437907	0.920396	0.123*
H1E	0.933327	0.435070	0.880484	0.123*
C2	0.7839(3)	0.47789(11)	0.76527(16)	0.0636(6)
H2A	0.695443	0.508595	0.764521	0.076*
H2B	0.853418	0.505749	0.724477	0.076*
C3	0.66726(19)	0.40382(9)	0.61672(13)	0.0405(4)
C4	0.65122(18)	0.32779(9)	0.56748(12)	0.0356(4)
C5	0.57731(18)	0.32087(9)	0.46539(13)	0.0358(4)
C6	0.68582(17)	0.19993(9)	0.43730(13)	0.0362(4)
C7	0.75556(17)	0.19973(9)	0.53939(12)	0.0362(4)
C8	0.72126(18)	0.25723(9)	0.62582(12)	0.0356(4)
H8	0.813414	0.273607	0.665851	0.043*
C9	0.86593(19)	0.14203(9)	0.56841(13)	0.0412(4)
C10	0.82475(19)	0.09076(9)	0.38317(13)	0.0432(4)
C11	0.71586(18)	0.14441(9)	0.35368(13)	0.0390(4)
C12	0.6459(2)	0.14179(10)	0.24681(14)	0.0508(5)
H12	0.572176	0.177090	0.225675	0.061*

<https://doi.org/10.1515/ncrs-2018-0110>

Received April 10, 2018; accepted June 27, 2018; available online July 13, 2018

Abstract

C₂₂H₁₉NO₆, monoclinic, $P2_1/n$ (no. 14), $a = 9.195(4)$ Å, $b = 17.253(5)$ Å, $c = 12.127(5)$ Å, $\beta = 95.100(16)^\circ$, $V = 1916.4(12)$ Å³, $Z = 4$, $R_{\text{gt}}(F) = 0.0405$, $wR_{\text{ref}}(F^2) = 0.1084$, $T = 296(2)$ K.

CCDC no.: 1851952

The crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Source of material

A mixture of 4-hydroxycoumarin (10 mmol), 3-methoxybenzaldehyde (10 mmol), ethyl cyanoacetate

*Corresponding author: Liangyu Zhang, Department of Oncology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, P.R. China, e-mail: liangyu_zhang666@yeah.net

Lei Shi: Department of Gynaecology and Obstetrics, Daqing Oilfield General Hospital, Daqing, Heilongjiang, P.R. China

Dehui Zhang: Department of Oncology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, P.R. China

Table 2 (continued)

Atom	x	y	z	$U_{\text{iso}}^*/U_{\text{eq}}$
C13	0.6859(2)	0.08683(11)	0.17235(15)	0.0600(5)
H13	0.639418	0.085091	0.101066	0.072*
C14	0.7948(2)	0.03466(11)	0.20428(16)	0.0612(6)
H14	0.821873	−0.001972	0.153675	0.073*
C15	0.8647(2)	0.03555(11)	0.30962(16)	0.0566(5)
H15	0.937364	−0.000385	0.330596	0.068*
C16	0.62571(18)	0.22146(9)	0.70925(12)	0.0378(4)
C17	0.5164(2)	0.16963(10)	0.67677(14)	0.0481(4)
H17	0.501334	0.154756	0.602927	0.058*
C18	0.4288(2)	0.13959(11)	0.75320(16)	0.0570(5)
H18	0.355116	0.104679	0.730420	0.068*
C19	0.4498(2)	0.16097(11)	0.86284(15)	0.0546(5)
H19	0.390564	0.140569	0.913951	0.065*
C20	0.5589(2)	0.21266(10)	0.89649(14)	0.0460(4)
C21	0.64754(19)	0.24259(10)	0.82025(13)	0.0435(4)
H21	0.721994	0.276966	0.843360	0.052*
C22	0.6966(3)	0.27477(14)	1.04759(16)	0.0734(7)
H22A	0.693073	0.283923	1.125394	0.110*
H22B	0.783559	0.246354	1.035663	0.110*
H22C	0.697183	0.323460	1.009323	0.110*

(10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2–3 h and then cooled to room temperature. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under reduced pressure.

Experimental details

H atoms bonded to C and N atoms were positioned geometrically and refined using a riding model, with C–H = 0.96 Å and N–H = 0.86 Å with $U_{\text{iso}}(\text{H}) = 1.2$ times $U_{\text{eq}}(\text{C})$ and 1.2 times $U_{\text{eq}}(\text{N})$.

Comment

The progress achieved in the synthesis of heterocyclic compounds with biological potential is due to improvement of the methodological study of tested substances [1]. It is known that many coumarin derivatives have biological activity [2]. Ovarian cancer is a cancer that forms in or on an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. Symptoms become noticeable as the cancer progresses. These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others. Common areas to which the cancer may spread include the lining of the abdomen, lymph nodes, lungs, and liver. Recent research indicated that the use of pyran-based

heterocycles is an effective treatment to shrink ovarian cancer and control symptoms [3–5].

In the title crystal structure (Figure), the dihedral angle of the six-membered ring containing one O atom [C(4), C(5), O(3), C(6), C(7) and C(8)] and the adjacent six-membered carbon ring [C(16)–C(21)] is $\sim 83^\circ$. The bond distances of C–O, C–N and C–C are in their normal ranges and they can be compared with those in previously reported complexes. Comparable with the known similar structures in the reference [6–8], the most difference is that they own different functional groups. The one -OCH₃ group or H atom in the title compound were replaced by other atoms or functional groups such as Cl atom and -CH₃ group (Ref. 6), Cl atom (Ref. 7) and -NO₂ group (Ref. 8).

References

- Song, Y.; Li, N.; Gu, J.; Fu, S.; Peng, Z.; Zhao, C.; Zhang, Y.; Li, X.; Wang, Z.; Li, X.; Liu, G.: β -Hydroxybutyrate induces bovine hepatocyte apoptosis via an ROS-p38 signaling pathway. *J. Dairy Sci.* **99** (2016) 9184–9198.
- Sun, X.; Yuan, X.; Chen, L.; Wang, T.; Wang, Z.; Sun, G.; Li, X.; Li, X.; Liu, G.: Histamine induces bovine rumen epithelial cell inflammatory response via NF- κ B pathway. *Cell. Physiol. Biochem.* **42** (2017) 1109–1119.
- Li, J.; Meng, J.; Qu, D.; Zhang, Z.-D.; Li, F.; Yang, X.-H.; Li, J.-T.; Li, M.-K.: New biscoumarin and dihydropyran derivatives as antimicrobials. *Res. Chem. Intermed.* **41** (2015) 8257–8267.
- Wu, W.-X.; Zhang, Q.; Hu, X.: New 4-arylpolyhydroquinoline derivatives: inhibiting growth of oral tumor cells. *Lat. Am. J. Pharm.* **36** (2017) 816–819.
- Shi, D.-Q.; Zhang, S.; Wang, X.-S.; Zhuang, Q.-Y.: Ethyl 2-amino-4-(4-fluorophenyl)-7,7-dimethyl-5-oxo-5,6,7,8-tetrahydro-4H-benzo[b]pyran-3-carboxylate. *Acta Crystallogr.* **E59** (2003) o1501–o1502.
- Srinivasan, L.; Anandalwar, S. M.; Prasad, J. S.; Manvar, D.; Parecha, A.; Shah, A.: Synthesis and crystal structure of 2-amino-4-(3'-chlorophenyl)-3-ethoxycarbonyl-4H-pyrano-[3,2-c]-chromene-5-one. *Anal. Sci.* **22** (2006) X97–X98.
- Hu, X.; Song, L.: Ethyl 2-amino-4-(3-chlorophenyl)-5,10-dioxo-5,10-dihydro-4H-benzo[g]-chromene-3-carboxylate. *Acta Crystallogr.* **E65** (2009) o1324–o1324.
- Wang, X.-S.; Zeng, Z.-S.; Shi, D.-Q.; Chen, H.; Wei, X.-Y.; Zong, Z.-M.: Methyl 2-amino-4-(3-nitrophenyl)-5-oxo-5,6-dihydro-4H-pyrano[3,2-c]quinoline-3-carboxylate dimethylformamide solvate. *Acta Crystallogr.* **E60** (2004) o1877–o1879.
- Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H.: OLEX2: a complete structure solution, refinement and analysis program. *J. Appl. Crystallogr.* **42** (2009) 339–341.
- Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr.* **C71** (2015) 3–8.
- Bruker. SAINT, APEX2 and SADABS. Bruker AXS Inc., Madison, WI, USA (2009).